Asset Details
Do you wish to reserve the book?
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
Do you wish to request the book?
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series
2024
Overview
Background
Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile comparable to aflibercept 2 mg in pivotal and phase 3 studies, reporting such cases in clinical practice helps evaluate potential risk of these agents.
Case presentation
In this case series, a cluster of 8 patients manifesting acute intraocular inflammation (IOI) after intravitreal aflibercept 8 mg injection at three different centers are described. All patients developed inflammation of the vitreous and anterior chamber within 2–17 days following the injection. All subjects had previously received intravitreal anti-vascular endothelial growth factor (VEGF) therapy (ranibizumab, aflibercept 2 mg or faricimab) without injection-related complications. No signs of vasculitis, papillitis or retinitis were noted. In view of the clinical presentation, vitreous cultures were not performed. Inflammation resolved with topical steroids and non-steroidal anti-inflammatory drugs over a course of 11–24 days with excellent visual recovery.
Conclusions
We report a cluster of injection-related ocular inflammation following intravitreal aflibercept 8 mg with at present unknown cause. It underlines the need for clinical awareness to detect such cases despite the low-risk safety profile in pivotal studies.
Publisher
BioMed Central,Springer Nature B.V,BMC
Subject
/ Aged
/ Angiogenesis Inhibitors - administration & dosage
/ Angiogenesis Inhibitors - adverse effects
/ Clinics
/ Diabetes
/ Edema
/ Endophthalmitis - chemically induced
/ Endophthalmitis - drug therapy
/ Female
/ Females
/ Humans
/ Male
/ Medicine
/ Nonsteroidal anti-inflammatory drugs
/ Pain
/ Receptors, Vascular Endothelial Growth Factor - administration & dosage
/ Recombinant Fusion Proteins - administration & dosage
/ Recombinant Fusion Proteins - adverse effects
/ Steroids
/ Uveitis - chemically induced
/ Vascular endothelial growth factor
/ Vascular Endothelial Growth Factor A - antagonists & inhibitors
